TMO Quote, Financials, Valuation and Earnings

Fonar has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of 12.56%. Thermo Fisher Scientific's return on equity of 13.08% beat Fonar's return on equity of 6.13%.

Thermo Fisher Scientific has a consensus price target of $649.80, signalling upside risk potential of 22.84%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Thermo Fisher Scientific has higher upside potential than Fonar, analysts believe Thermo Fisher Scientific is more attractive than Fonar.

Thermo Fisher Scientific has a beta of 0.767, which suggesting that the stock is 23.35% less volatile than S&P 500. In comparison Fonar has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.004%.

Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.3%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than Fonar quarterly revenues of $25M. Thermo Fisher Scientific's net income of $1.6B is higher than Fonar's net income of $3.1M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.16x while Fonar's PE ratio is 10.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.80x versus 0.95x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of -209.38%. Thermo Fisher Scientific's return on equity of 13.08% beat ProPhase Labs's return on equity of -59.59%.

Thermo Fisher Scientific has a consensus price target of $649.80, signalling upside risk potential of 22.84%. On the other hand ProPhase Labs has an analysts' consensus of -- which suggests that it could grow by 2836.51%. Given that ProPhase Labs has higher upside potential than Thermo Fisher Scientific, analysts believe ProPhase Labs is more attractive than Thermo Fisher Scientific.

Thermo Fisher Scientific has a beta of 0.767, which suggesting that the stock is 23.35% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.316, suggesting its less volatile than the S&P 500 by 131.62%.

Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.3%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than ProPhase Labs quarterly revenues of $3.1M. Thermo Fisher Scientific's net income of $1.6B is higher than ProPhase Labs's net income of -$6.6M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.16x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.80x versus 0.91x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of 13.08%. Thermo Fisher Scientific's return on equity of 13.08% beat Veracyte's return on equity of -0.84%.

Thermo Fisher Scientific has a consensus price target of $649.80, signalling upside risk potential of 22.84%. On the other hand Veracyte has an analysts' consensus of -- which suggests that it could grow by 4.96%. Given that Thermo Fisher Scientific has higher upside potential than Veracyte, analysts believe Thermo Fisher Scientific is more attractive than Veracyte.

Thermo Fisher Scientific has a beta of 0.767, which suggesting that the stock is 23.35% less volatile than S&P 500. In comparison Veracyte has a beta of 1.690, suggesting its more volatile than the S&P 500 by 69.047%.

Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.3%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than Veracyte quarterly revenues of $115.9M. Thermo Fisher Scientific's net income of $1.6B is higher than Veracyte's net income of $15.2M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.16x while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.80x versus 7.35x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 15.38% compared to Thermo Fisher Scientific's net margin of -56.4%. Thermo Fisher Scientific's return on equity of 13.08% beat XWELL's return on equity of -71.82%.

Thermo Fisher Scientific has a consensus price target of $649.80, signalling upside risk potential of 22.84%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 345.86%. Given that XWELL has higher upside potential than Thermo Fisher Scientific, analysts believe XWELL is more attractive than Thermo Fisher Scientific.

Thermo Fisher Scientific has a beta of 0.767, which suggesting that the stock is 23.35% less volatile than S&P 500. In comparison XWELL has a beta of 2.426, suggesting its more volatile than the S&P 500 by 142.629%.

Thermo Fisher Scientific has a quarterly dividend of $0.39 per share corresponding to a yield of 0.3%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 8.72% of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific quarterly revenues are $10.6B, which are larger than XWELL quarterly revenues of $8.4M. Thermo Fisher Scientific's net income of $1.6B is higher than XWELL's net income of -$4.8M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 33.16x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 4.80x versus 0.20x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.